Myriad Genetics Stock Forecast
NASDAQ: MYGNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 9, 1:13 PM ET
MYGN analyst consensus
Consensus (9 analysts)
hold
Avg. price target
$3.91-8.54%
- Strong buy 0
- Buy 1
- Hold 5
- Sell 1
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Myriad Genetics (2026-10-08), 1 rate the stock a buy or strong buy, 5 rate it a hold and 3 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $3.91, with a high estimate of $8.00 and a low estimate of $2.00. The average target implies downside of 8.5% from the current price of $4.28.
The spread between the highest and lowest targets is 300.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MYGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 11% |
| Hold | 5 | 56% |
| Sell | 1 | 11% |
| Strong sell | 2 | 22% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | -53.22% |
| Average target | $3.91 | -8.54% |
| High target | $8.00 | +87.13% |